The arrival of COVID-19 vaccines has raised hope for an end to the pandemic. Hopefully that’s true, but there are variables. Here are some factors that could affect the success of the vaccine rollout.
L’expertise universitaire, l’exigence journalistique
Articles sur Pfizer-BioNTech vaccine
Affichage de 101 à 120 de 148 articles
Americans with excess weight and obesity have been hit hard by COVID-19. Now there is reason to believe they may not get the same protection from the vaccines.
Vaccine hesitancy will not go away fast. In fact, there are parallels in the physical world to how quickly or slowly an object returns to its normal state.
The approval of the first of four COVID-19 vaccines marks the first step in New Zealand’s plans for a Pacific-wide immunisation rollout.
A recommendation from a German vaccine advisory body not to give the AstraZeneca vaccine to people aged over 65 has caused concern. But we should interpret this advice with caution.
Tensions run high as EU vaccine deliveries fall behind schedule, while new vaccines are being created to handle mutant viral strains.
Israel is vaccinating its population at an impressive rate and sharing the data with the world. But at what price?
The COVID-19 vaccine rollout has fallen far short of President Trump’s promises. President Biden says he can fix that. Can he?
Two pharmacists involved in COVID-19 vaccine preparation explain the role pharmacists are poised to play in expanding vaccine access.
Perhaps you’ve heard mRNA vaccines cause autoimmune disease, or connect you to the internet. Now the Pfizer vaccine has been approved in Australia, it’s important we iron out these misconceptions.
Historically, we immunized children against diseases like polio that were a clear danger to them, but COVID-19 is usually mild in children. However, herd immunity is unlikely without vaccinating kids.
With richer countries having bought up most of the leading western vaccines, others are looking to India, China and Russia for supplies.
We have limited information about the reported deaths of 30 elderly people in Norway who had received the Pfizer COVID vaccine. Here’s what we do know.
Rollout of COVID-19 vaccines has begun. But getting the jab doesn’t mean abandoning masks, distancing and handwashing. Here’s why the current preventive measures must continue post-vaccine.
In our first weekly update on COVID vaccines, we consider how roll-out plans are being tweaked and when it’s likely we’ll start to see vaccines having an impact.
Two in five Americans say they don’t want a COVID-19 vaccine, which is a problem. Finding out what Americans do want from a vaccine might help.
The best approach for protecting everyone’s health will require us to provide different vaccines to different people according to need and availability.
With reports emerging of vaccine wastage across the world, medical supply chain experts explain why that’s to be expected.
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it’s better to give one dose to more people and give a second when the supply is better.
The shipment of goods to suppliers has become technologically sophisticated. Delays in getting out the COVID-19 vaccine to people show that the breakdowns come down to something more basic.
Les contributeurs les plus fréquents
-
Professor of Medicine, University of Virginia
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Associate Professor of Pediatrics, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Chair in Epidemiology, Deakin University
-
Instructor of Human Immunology, Emory University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Associate Professor in Viral Immunology, University of Birmingham
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
